Cancers, Год журнала: 2025, Номер 17(3), С. 555 - 555

Опубликована: Фев. 6, 2025

Cholangiocarcinoma is a rare primary liver cancer with poor prognosis, due to the advanced stage at time of diagnosis and limited therapeutic options, response. Chemotherapy remains standard first-line treatment, but advent immunotherapy has recently induced promising results. Given fact that frequency increasing nowadays survival rate very low, it crucial recognize patients who are suitable for will have best Different types biomarkers, such as interleukins, exosomes, mi-RNA, ctDNA, gene mutations, been studied their feasibility, not only early biliary tract also determination responsiveness in treatment. Less frequently, these studies focus on finding observing biomarkers receive immunotherapy. This review aims summarize current knowledge existing/promising unresectable or metastatic cholangiocarcinoma, treated monotherapy, combined chemotherapy.

Язык: Английский